ORIC - NASDAQ

ORIC Pharmaceuticals, Inc.

ORIC·NASDAQ

$8.04

+5.6%

HealthcareBiotechnology

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$832.80M

EPS-1.4700

P/E Ratio-5.47

Earnings Date08/06/2026

411.00M

Assets

50%

3Y+64.0%

5Y+37.0%

10Y+1269.0%

26.64M

Total Liabilities

-14%

3Y-5.0%

5Y+189.0%

10Y+520.0%

384.36M

Total Equity

58%

3Y+73.0%

5Y+33.0%

10Y+1394.0%

ORIC Pharmaceuticals, Inc. Funding & Solvency Profile

ORIC · NASDAQ

Current Assets

Cash & Cash Equivalents45.67M

Net Receivables0.00

Inventory0.00

Other Current Assets6.98M

Total Current Assets288 M

Non-Current Assets

Property, Plant & Equipment9.07M

Goodwill & Intangible Assets0.00

Long-Term Investments111.25M

Other Non-Current Assets98.00K

Total Non-Current Assets120 M

Total Assets

411.00M

Financial Health Analysis

Current Ratio

14.13x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.07x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

268 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

70% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ORIC Pharmaceuticals, Inc. Balance Sheet

ORIC • NASDAQ

ORIC Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	45.7M	59.4M	23.4M	66.8M	226M	78.4M	89.2M	42.6M	25.8M
Short-Term Investments	235.8M	196.6M	184.8M	139.4M	11M	215.2M	0.0	0.0	0.0
Cash & Short-Term Investments	281.5M	256M	208.2M	206.3M	237M	293.6M	89.2M	42.6M	25.8M
Prepaids	0.0	0.0	0.0	0.0	3.5M	3.1M	840K	1.1M	791K
Other Current Assets	7M	6.3M	4.4M	4.2M	0.0	0.0	0.0	0.0	0.0
Total Current Assets	288.5M	262.3M	212.6M	210.5M	240.5M	296.7M	90M	43.7M	26.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	9.1M	2.9M	12M	14.3M	2.4M	2M	2.2M	2.5M	2.9M
Long-Term Investments	111.3M	0.0	27.3M	22.4M	43.4M	0.0	0.0	0.0	0.0
Tax Assets	2.1M	0.0	2.7M	3.2M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	98K	9M	61K	49K	12.3M	319K	1.9M	496K	513K
Total Non-Current Assets	122.5M	11.9M	42.1M	39.9M	58.1M	2.3M	4.1M	3M	3.4M
Total Assets	411M	274.1M	254.7M	250.4M	298.6M	299M	94.1M	46.7M	30M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.8M	1.5M	944K	1.3M	1.9M	757K	152K	446K	940K
Accounts Payable	3.8M	1.5M	944K	1.3M	1.9M	757K	152K	446K	940K
Accrued Expenses	0.0	12.5M	6.5M	5.3M	6.5M	7.7M	3.5M	1.6M	834K
Short Term Debt	3.3M	0.0	2.8M	2.7M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.2M	0.0	0.0	1.9M	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	546K	495K	438K	388K
Other Current Liabilities	13.3M	7.6M	10.2M	6.1M	4.8M	0.0	1.2M	115K	448K
Total Current Liabilities	20.4M	24.8M	20.5M	15.4M	15.2M	9M	5.4M	2.6M	2.6M
NON-CURRENT LIABILITIES
Long Term Debt	4.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	765K	1.3M	1.7M
Deferred Tax Liabilities (Non-Current)	2.1M	0.0	2.7M	3.2M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-4.1M	6.2M	0.0	0.0	10.5M	219K	0.0	107.3M	0.0
Total Non-Current Liabilities	6.2M	6.2M	10.1M	12.6M	10.5M	219K	765K	108.6M	1.7M
Capital Lease Obligations	4.1M	3.2M	7.5M	9.4M	1.9M	0.0	0.0	0.0	0.0
Total Liabilities	26.6M	31M	30.6M	28M	25.7M	9.2M	6.1M	111.2M	4.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	178.1M	107.3M	69.3M
Common Stock	11K	7K	6K	5K	4K	4K	2K	1K	1K
Additional Paid-In Capital	1.1B	805.5M	658.8M	557.9M	518.2M	456.2M	2.6M	1.4M	832K
Retained Earnings	-692.2M	-562.8M	-434.9M	-334.2M	-245.1M	-166.4M	-92.7M	-65.8M	-44.4M
Accumulated Other Comprehensive Income/Loss	786K	379K	258K	-1.3M	-103K	-31K	-3.5M	-2.6M	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6M	0.0
Total Stockholders' Equity	384.4M	243.1M	224.1M	222.4M	273M	289.8M	88M	-64.4M	25.7M
Total Equity	384.4M	243.1M	224.1M	222.4M	273M	289.8M	88M	-64.4M	25.7M
SUMMARY
Total Liabilities & Equity	411M	274.1M	254.7M	250.4M	298.6M	299M	94.1M	46.7M	30M
Total Investments	346.6M	196.6M	212.1M	161.9M	54.4M	215.2M	0.0	0.0	0.0
Total Debt	11.6M	3.2M	10.2M	12.1M	1.9M	0.0	0.0	0.0	0.0
Net Debt	-34.1M	-56.2M	-13.2M	-54.7M	-224.1M	-78.4M	-89.2M	-42.6M	-25.8M
Shares Outstanding	97,122,987	97,122,987	97,122,987	97,122,987	97,122,987	97,122,987	97,122,987	97,122,987	97,122,987

SEC Filings

ORIC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 04, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 23, 2026	February 23, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing

Showing 1 to 10 of 99 filings

Related Guides

Blog Categories

Continue your ORIC research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.